Drug Profile
Paclitaxel-eluting resorbable scaffold - Lyra Therapeutics
Alternative Names: Paclitaxel-eluting stent - Lyra Therapeutics; Stanza DRS; Stanza Drug-eluting Resorbable ScaffoldLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator 480 Biomedical
- Developer Lyra Therapeutics
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Peripheral arterial disorders
Most Recent Events
- 26 Sep 2018 480 Biomedical is now called Lyra Therapeutics
- 01 Aug 2016 Paclitaxel-eluting resorbable scaffold is still in phase III trials for Peripheral arterial disorders in Austria, Germany, New Zealand and Switzerland (Intra-arterial) (NCT02097082)
- 31 Oct 2013 Phase-III clinical trials in Peripheral arterial disorders in Austria, Germany, New Zealand and Switzerland (Intra-arterial) (NCT02097082) (EudraCT2013-002467-26)